AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q1 FY24 results · Apr–Jun 2023
AstraZeneca Pharma India reported revenue from operations of ₹295.47 crore (up 27.2% from Q1 FY23) and net profit of ₹53.86 crore (up 167.3% from Q1 FY23) for Q1 FY24 (Apr–Jun 2023), on a standalone basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 295.47 | 232.33 | +27.2% | 284.70 | +3.8% |
| Other income | 8.10 | 4.11 | +97.0% | 8.00 | +1.3% |
| Total income | 303.57 | 236.45 | +28.4% | 292.70 | +3.7% |
| Profit before tax | 71.40 | 27.30 | +161.5% | 23.28 | +206.7% |
| Net profit for the period | 53.86 | 20.15 | +167.3% | 17.27 | +211.9% |
| EPS, basic (₹) | 21.54 | 8.06 | +167.3% | 6.91 | +211.9% |
| Net margin (%) | 18.2 | 8.7 | 6.1 |
Standalone
- Filed with BSE
- 14 Aug 2023, 16:54 IST
- Board meeting
- 14 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE